What is the current stock price of Kaleido Biosciences, Inc. (KLDO)?

As of the latest market data, Kaleido Biosciences, Inc. (KLDO) is trading at $0.00. The stock has seen a loss of 0.00% today.

Does Kaleido Biosciences, Inc. (KLDO) pay a dividend?

Based on current data, Kaleido Biosciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Kaleido Biosciences, Inc.?

The current market capitalization of Kaleido Biosciences, Inc. (KLDO) is approximately unavailable.

KLDO

Kaleido Biosciences, Inc.·Healthcare

0.00

0.000%(+0.00)

Market Closed

Last Updated: — ET

52W L: $0.0052W H: $0.19

KLDO NEWS

defenseworld.net

Feb 18

Contrasting Kaleido Biosciences (NASDAQ:KLDO) and Adial Pharmaceuticals (NASDAQ:ADIL)

Adial Pharmaceuticals (NASDAQ: ADIL - Get Free Report) and Kaleido Biosciences (NASDAQ: KLDO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends. Profitability This table compares Adial Pharmaceuticals and

Company Profile

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2019-02-28

Beta

-1.17

Websitekaleido.com↗